NCT07169708View on ClinicalTrials.gov

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions
Non Small Cell Lung Cancer NSCLC
Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Ono Pharmaceutical Co. Ltd

INDUSTRY

NCT07169708 - A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) | Biotech Hunter | Biotech Hunter